Vairaperumal Tharmaraj, Tsai Zong-Yun, Liu Ping-Yen
Institute of Clinical Medicine, College of Medicine, National Cheng Kung University.
Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Acta Cardiol Sin. 2024 Jul;40(4):367-372. doi: 10.6515/ACS.202407_40(4).20240624A.
The coronary slow-flow (CSF) phenomenon is a condition characterized by delayed coronary opacification during diagnostic angiography without the presence of epicardial coronary artery disease. This mini-review explores various emerging predictors and biomarkers associated with CSF, aiming to address the potential diagnostic tools. A comprehensive analysis of recent studies has investigated different biomarkers, including growth differentiation factor 15, galectin 3, microRNA (miRNA)-22, miRNA-155, interleukin 34, soluble vascular cell adhesion molecule-1, long non-coding RNA, plasma choline, adropin, and lipid markers non-high-density lipoprotein cholesterol (HDL-C)/HDL-C ratio to enhance understanding and predict CSF. Additionally, we have summarizes the major findings and significant limitations observed in various studies on CSF biomarkers. The implications of these findings suggest significant advancements in personalized treatment strategies and improved prognostic outcomes for patients exhibiting CSF.
冠状动脉慢血流(CSF)现象是一种在诊断性血管造影过程中冠状动脉显影延迟且不存在心外膜冠状动脉疾病的情况。本综述探讨了与CSF相关的各种新兴预测指标和生物标志物,旨在探讨潜在的诊断工具。对近期研究的综合分析调查了不同的生物标志物,包括生长分化因子15、半乳糖凝集素3、微小RNA(miRNA)-22、miRNA-155、白细胞介素34、可溶性血管细胞粘附分子-1、长链非编码RNA、血浆胆碱、内脂素以及脂质标志物非高密度脂蛋白胆固醇(HDL-C)/HDL-C比值,以增进对CSF的理解并进行预测。此外,我们总结了各项关于CSF生物标志物研究中的主要发现和显著局限性。这些发现表明,对于表现出CSF的患者,个性化治疗策略和改善预后结果方面取得了重大进展。